DNMT1 and renal cell carcinoma: Another inhibitor of DNMT, the antisense oligodeoxynucleotide MG98 was intravenously administered at a dose of 360 mg/m2 twice weekly for three consecutive weeks out of four in 17 patients with advanced RCC receiving a median of two cycles with no objective responses.